Treating age-related macular degeneration - interaction of VEGF-antagonists with their target.
The neutralization of VEGF is the current treatment of choice for age-related macular degeneration. Current approaches include anti-VEGF-antibodies and -Fab Fragments, aptamers, soluble receptors (Traps) and siRNA. The molecular properties of VEGF and its antagonists are reviewed and the pathways of action of these substances are discussed.
Klettner
A
A
UK S-H, Department of Ophthalmology, Campus Kiel, Hegewischstr. 2, 24105 Kiel, Germany. aklettner@ophthalmol.uni-kiel.de
Roider
J
J
D000367:Age Factors; D000595:Amino Acid Sequence; D020533:Angiogenesis Inhibitors / Q000737:chemistry / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000737:chemistry / Q000627:therapeutic use*; D000068258:Bevacizumab; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D008969:Molecular Sequence Data; D034741:RNA, Small Interfering / Q000737:chemistry / Q000627:therapeutic use*; D000069579:Ranibizumab; D040262:Receptors, Vascular Endothelial Growth Factor / Q000737:chemistry / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000627:therapeutic use*; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D034741:RNA, Small Interfering; D011993:Recombinant Fusion Proteins; C475927:VEGF-Trap fusion protein, recombinant; D042442:Vascular Endothelial Growth Factors; C495058:pegaptanib; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab